• Characterization of the molecules in the lectin pathway of complement.
• Characterization of the initiation signals that determine activation of all complement pathways.
• Development of assays and antibodies for characterization of the complement system.
• Characterization of the role of the lectin pathway in opportunistic infections.

We are working to understand the structure and molecular genetics of the complement system in general and the lectin pathway in particular. We were the first to show the genetic regulation of mannose-binding lectin and other genes in the lectin pathway. We have shown their associations on infectious tendency, HIV progression, progression of cystic fibrosis, different autoimmune diseases as well as a risk factor for cardiovascular events. We were also the first to show the importance of the so called ficolin protein family in innate immune defense in a human setting as well as the collectin-related protein family. We have discovered a novel endogenous protein named MAP-1, which has been shown to regulate the function of the lectin pathway, but also coagulation pathways. We have also been heavily involved in developing new biomarkers for clinical use. In recent years our group has been working mostly on understanding the role of complement particularly in atherosclerosis and fungal infections.  We are also hosting a Hybridoma Facility for scientific and contract production of monoclonal antibodies. Our group consists of around 15 dedicated and enthusiastic researchers with laboratory facilities at the main university hospital in the middle of Copenhagen.